What predicts the clinical benefits of PARP inhibitors in platinum-sensitive recurrent ovarian cancer: A real-world single-center retrospective cohort study from China

What predicts the clinical benefits of PARP inhibitors in platinum-sensitive recurrent ovarian cancer: A real-world single-center retrospective cohort study from China

ObjectiveThis study assessed the real-world application, effectiveness, and safety of olaparib and niraparib as maintenance therapies in patients with platinum-sensitive recurrent ovarian cancer (PSROC) in China and investigated clinical factors associated with prolonged benefits of poly ADP-ribose...

Full description

Bibliographic Details
Main Authors: Depu Zhang, Shuo Li, Xinxin Zhang, Jingwei Peng, Shiqian Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Oncology
Subjects:
olaparib
niraparib
PARP inhibitor
ovarian cancer
prognosis
real world
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.955124/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.955124/full

Similar Items